NVO - Novo Nordisk A/S

NYSE - NYSE Delayed price. Currency in USD
43.12
-0.05 (-0.12%)
At close: 4:02PM EDT

43.11 -0.01 (-0.03%)
After hours: 4:26PM EDT

Stock chart is not supported by your current browser
Previous close43.17
Open43.20
Bid42.50 x 800
Ask44.00 x 2200
Day's range42.98 - 43.25
52-week range41.23 - 58.37
Volume860,248
Avg. volume1,579,406
Market cap103.106B
Beta (3Y monthly)0.85
PE ratio (TTM)17.28
EPS (TTM)2.50
Earnings dateN/A
Forward dividend & yield1.27 (2.92%)
Ex-dividend date2018-08-17
1y target est47.20
Trade prices are not sourced from all markets
  • How Novartis’s Innovative Medicines Business Performed in Q3
    Market Realist4 hours ago

    How Novartis’s Innovative Medicines Business Performed in Q3

    Novartis’s (NVS) Innovative Medicines business includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. The Innovative Medicines business contributed over 67.2% of the total revenues for Novartis and saw 6% growth in year-over-year (or YoY) revenues to ~$8.6 billion during the third quarter of 2018.

  • Novo Nordisk (NVO) Faces Pricing Pressure and Competition
    Zacks4 days ago

    Novo Nordisk (NVO) Faces Pricing Pressure and Competition

    Novo Nordisk (NVO) faces pricing pressures and intense competition in the Diabetes market.

  • PFE or NVO: Which Is the Better Value Stock Right Now?
    Zacks7 days ago

    PFE or NVO: Which Is the Better Value Stock Right Now?

    PFE vs. NVO: Which Stock Is the Better Value Option?

  • Healthcare Stocks in the Red amid Broader Market Sell-Off
    Market Realist11 days ago

    Healthcare Stocks in the Red amid Broader Market Sell-Off

    Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.

  • How Novartis’s Businesses Have Been Performing
    Market Realist12 days ago

    How Novartis’s Businesses Have Been Performing

    Novartis’s (NVS) business is separated into three segments: Innovative Medicines, the prescription medicines business Sandoz, the generics business Alcon, the eye care business

  • GW Pharmaceuticals: Recommendations and Market Capitalization
    Market Realist17 days ago

    GW Pharmaceuticals: Recommendations and Market Capitalization

    GW Pharmaceuticals (GWPH) has developed prescription medicines derived from the cannabis plant for the treatment of spasticity from multiple sclerosis. Its portfolio includes clinical stage cannabinoid products focused on the treatment of neurological conditions.

  • Lilly's Novel Diabetes Candidate Shows Promise in Phase II
    Zacks17 days ago

    Lilly's Novel Diabetes Candidate Shows Promise in Phase II

    Lilly's (LLY) dual GIP and GLP-1 receptor agonist demonstrates impressive reduction in blood sugar levels as well as body weight in type II diabetes patients.

  • Bloomberg18 days ago

    Diabetes Drug's Results Push Lilly to Look at Obesity Too

    The drug showed an average reduction of as much as 12.7 percent in weight and up to 2.4 percent in blood sugar in the midstage research, Lilly said in a statement Thursday. Lilly rose 4.2 percent to $113.10 in New York before U.S. exchanges opened. The company now plans “very broad” late-stage studies in diabetes that will likely begin by early 2019 and look at different drug combinations, said Brad Woodward, senior medical director at Lilly’s diabetes unit.

  • How GlaxoSmithKline’s Vaccines Business Has Performed Recently
    Market Realist20 days ago

    How GlaxoSmithKline’s Vaccines Business Has Performed Recently

    GlaxoSmithKline’s (GSK) Vaccines segment includes influenza vaccines, meningitis vaccines, shingles vaccines, and established vaccines. The vaccines segment reported revenues of ~1.3 billion pounds during the second quarter of 2018, a 13% increase in YoY revenues. The growth includes a 16% increase in operating revenues offset by a 3% negative impact of foreign exchange during the quarter.

  • How GlaxoSmithKline’s Segments Performed
    Market Realist21 days ago

    How GlaxoSmithKline’s Segments Performed

    GlaxoSmithKline (GSK) has three business segments: the Pharmaceuticals segment, the Vaccines segment, and the Consumer Healthcare segment. We’ll discuss how the company’s segments performed in this article.

  • Sanofi Stock Up 2.8% in September: What Lies Ahead?
    Market Realist24 days ago

    Sanofi Stock Up 2.8% in September: What Lies Ahead?

    On September 27, Sanofi’s (SNY) closing price was $44.84, and its market capitalization was $110.7 billion. The stock rose 1.2% that day from its previous day’s closing price. It traded at its 52-week high of $50.64 on October 6, 2017. It registered its 52-week low of $37.43 on May 9, 2018. Currently, SNY stock is trading above its 50-day moving average of $42.89 as well as its 200-day moving average of $40.89.

  • A Look at Eli Lilly’s Revenue Growth Rate
    Market Realist24 days ago

    A Look at Eli Lilly’s Revenue Growth Rate

    Eli Lilly and Company (LLY) reported revenue of ~$6.4 billion in the second quarter, surpassing Wall Street analysts’ estimates for revenue in the period.

  • Sanofi Stock: How Much Upside Potential Does Wall Street See?
    Market Realist24 days ago

    Sanofi Stock: How Much Upside Potential Does Wall Street See?

    Sanofi (SNY) is a global biopharmaceutical company, headquartered in France, with a market capitalization of $110.7 billion. It offers an expansive product portfolio that offers solutions across disease segments, including multiple sclerosis, immunology, neurology, oncology, cardiovascular diseases, diabetes, vaccines, infectious diseases, and rare disease disorders.

  • Investing in Diabetes Stocks: A Beginner's Guide
    Motley Fool25 days ago

    Investing in Diabetes Stocks: A Beginner's Guide

    Want to put money to work in this $825 billion market? Here's what you need to know.

  • Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff
    Zackslast month

    Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff

    Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.

  • GlobeNewswirelast month

    EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress

    -Substantial progress made in the Company’ s accelerated transformation into a commercial entity. -YUTIQ™ PDUFA date of November 5, 2018. -Commercial preparations underway for launch of DEXYCU™ in the ...

  • GlobeNewswirelast month

    EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors

    EyePoint Pharmaceuticals (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company’s Board of Directors has elected Göran Ando, M.D., as its next Chairman of the Board. As part of this transition, David J. Mazzo, Ph.D., will step-down as Non-Executive Chairman, but will remain on the Board and will continue to serve as Chair of the Compensation Committee. “We are pleased to have Dr. Ando serve as our Chairman of the Board as we continue our transition into a commercial-stage specialty pharmaceuticals company,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals.

  • Novartis to Divest Portions of Sandoz US to Aurobindo
    Market Realist2 months ago

    Novartis to Divest Portions of Sandoz US to Aurobindo

    Novartis (NVS) announced today, September 6, that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA for $0.9 billion in cash and $0.1 billion in potential earn-outs. The select portions include the Sandoz US dermatology business and the generic US oral solids business. The deal includes ~300 products and additional development programs that will be transferred from Sandoz’s US portfolio to Aurobindo.

  • Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)
    Zacks2 months ago

    Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)

    Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.

  • Novartis’s Key Developments in August
    Market Realist2 months ago

    Novartis’s Key Developments in August

    As we’ve already seen, Novartis (NVS) reported a 7% growth YoY (year-over-year) in revenues to ~$13.16 billion during Q2 2018.

  • Novartis’s Sandoz in Q2 2018
    Market Realist2 months ago

    Novartis’s Sandoz in Q2 2018

    Sandoz is Novartis’s (NVS) generics business and is a market leader in differentiated generics. Sandoz reported nearly flat revenues at ~$2.46 billion in Q2 2018 compared to $2.45 billion in the second quarter of 2017. Revenue growth was driven by a 2% favorable impact of foreign exchange, offset by a 2% decline in operating revenues.

  • Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events
    Zacks2 months ago

    Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events

    Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.

  • Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs
    Zacks2 months ago

    Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs

    Allergan (AGN) gets CRL for uterine fibroids candidate, Esmya. Merck (MRK) and Bristol-Myers' (BMY) PD-L1 inhibitors get FDA approval for expanded labels.

  • Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin
    Zacks2 months ago

    Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin

    Novo Nordisk A/S (NVO) acquires Ziylo Ltd. to speed up the development of glucose responsive insulins in a deal that could exceed $800 million.